<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00973505</url>
  </required_header>
  <id_info>
    <org_study_id>AN09021</org_study_id>
    <nct_id>NCT00973505</nct_id>
  </id_info>
  <brief_title>CYP19 Genetic Polymorphism &amp; Aromatase Inhibitor(AI)</brief_title>
  <acronym>AI-CYP19</acronym>
  <official_title>Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom &amp; Complication of Aromatase Inhibitor(AI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the relationship between the side
      effects(especially arthralgia and arthritis) which appear in the patients who are prescribed
      aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of SNPs (PCR &amp; sequencing), Estrogen, Inflammatory Cytokine level</measure>
    <time_frame>6, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EORTC (European Organization for Research and Treatment of Cancer)- QOL(Quality of Life)- C30, BR23 &amp; Skeletal pain information, BMI</measure>
    <time_frame>3,6,12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Arthralgia</condition>
  <condition>Arthritis</condition>
  <condition>Genetic Polymorphism</condition>
  <arm_group>
    <arm_group_label>CYP19</arm_group_label>
    <description>CYP19 genetic polymorphism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitor(Femara or Arimidex)</intervention_name>
    <description>Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd</description>
    <arm_group_label>CYP19</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients taking the medication of AI (aromatase inhibitor) in post menopause
        status.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must sign the informed consent.

          2. The patient must sign the informed consent of genetic screening test.

          3. The patient must be between 18 years old and 80 years old who can make a decision
             independently.

          4. The patient must be post-menopause status.

          5. The patient should be the stage 1,2 or 3 of the breast cancer.

          6. The test result of the estrogen receptor or progesterone receptor is positive, so the
             patient should be taking the medication of AI (Aromatase Inhibitor).

        Exclusion Criteria:

          1. The patient is pre-menopause status.

          2. The test result of serum FSH level is below 30mU/ml.

          3. The test result of the hormone receptor(ER &amp; PR) is negative or unknown.

          4. Patient's breast cancer stage is 4 which has systemic metastatics.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun Sook Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eun Sook Lee, MD, PhD</last_name>
    <phone>82-2-920-6744</phone>
    <email>eslee@korea.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Anam Hopital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Sook Lee, MD, PhD</last_name>
      <phone>82-2-920-6744</phone>
      <email>eslee@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Eun Sook Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2009</study_first_submitted>
  <study_first_submitted_qc>September 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2009</study_first_posted>
  <last_update_submitted>September 8, 2009</last_update_submitted>
  <last_update_submitted_qc>September 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Eun Sook, Lee</name_title>
    <organization>Korea University Anam Hospital</organization>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Aromatase inhibitors</keyword>
  <keyword>Genetic polymorphisms</keyword>
  <keyword>Arthralgia</keyword>
  <keyword>Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

